OSE Immuno share rebounds after breaking through its 2.58 € support level
The Nantes-based biotech is rebounding sharply this Wednesday, ranking among the strongest gainers on the CAC All Shares. The rebound comes after the company announced an oral presentation of its Combi-TED trial at the annual congress of the European Society for Medical Oncology in Madrid, and just days before the publication of its half-year results.
A technical rebound running counter to an underlying trend that remains highly unfavorable
The OSE Immunotherapeutics share gains 4.57% to 2.70 € during the session, after closing the previous day at 2.582 €. The stock had even broken through its support level at 2.58 € during Tuesday, September 22 trading, touching a low of 2.55 €, before recovering. Today's rally erases some of the recent losses, but does not change the underlying picture: the share remains below its 20-day moving average at 2.91 € (gap of -7.22%) and its 50-day moving average at 3.12 € (gap of -13.46%), two averages acting as a ceiling on the chart for several weeks.
Resistance at 3.37 € appears still distant under these conditions. The RSI at 23 reflects a marked oversold configuration, consistent with the decline of more than 20% recorded over three months, and 54.6% over one year. Today's increase alleviates the recent decline without erasing its scale.
Combi-TED at ESMO and half-year results expected on September 28
The rebound coincides with the announcement published this morning: the main results of the phase 2 Combi-TED trial, which evaluates Tedopi in metastatic non-small cell lung cancer, will be presented orally at the ESMO 2026 congress in Madrid. This is a clinical milestone anticipated by industry specialists, which will provide the first public reading of data from this trial. Furthermore, OSE Immunotherapeutics' pipeline was recently expanded: Veloxis Pharmaceuticals, the licensed partner, treated the first patient in the phase 2 of VEL-101, a molecule initially developed by the Nantes-based company for rejection prevention in kidney transplantation, as indicated by a press release dated September 10. Regarding the financial calendar, the 2026 half-year results are expected on September 28, a milestone that will provide visibility on available cash and the progress of clinical programs.
